Effect of AC2993 (synthetic exendin-4) - administered alone or in combination with daclizumab - on islet function in patients with type I diabetes.

Trial Profile

Effect of AC2993 (synthetic exendin-4) - administered alone or in combination with daclizumab - on islet function in patients with type I diabetes.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2014

At a glance

  • Drugs Exenatide (Primary) ; Daclizumab
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jan 2010 Actual number of patients (47) added as reported by ClinicalTrials.gov.
    • 03 Jan 2009 Actual start date changed from 8 Jul 2003 to 1 Jul 2003 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top